Cargando…

Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential

BACKGROUND: Encapsulated follicular tumours with equivocal papillary thyroid carcinoma (PTC) type nuclear features continue to remain a challenge despite the recent attempts to classify these borderline lesions. The term ‘well differentiated tumour of uncertain malignant potential (WDT-UMP)’ was int...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamba Saini, Monika, Weynand, Birgit, Rahier, Jacques, Mourad, Michel, Hamoir, Marc, Marbaix, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407836/
https://www.ncbi.nlm.nih.gov/pubmed/25907675
http://dx.doi.org/10.1186/s13000-015-0262-8
_version_ 1782367965102997504
author Lamba Saini, Monika
Weynand, Birgit
Rahier, Jacques
Mourad, Michel
Hamoir, Marc
Marbaix, Etienne
author_facet Lamba Saini, Monika
Weynand, Birgit
Rahier, Jacques
Mourad, Michel
Hamoir, Marc
Marbaix, Etienne
author_sort Lamba Saini, Monika
collection PubMed
description BACKGROUND: Encapsulated follicular tumours with equivocal papillary thyroid carcinoma (PTC) type nuclear features continue to remain a challenge despite the recent attempts to classify these borderline lesions. The term ‘well differentiated tumour of uncertain malignant potential (WDT-UMP)’ was introduced to classify these tumours. The present study aimed to evaluate the role of a cell cycle regulator like cyclin D1 in these tumours along with assessment of other well established PTC markers like galectin-3, HBME-1, CK19. METHODS: Thirteen cases of metastatic PTC, papillary microcarcinoma and follicular variant of PTC (FVPTC) were identified from a histological review of 510 cases. In addition, 13 cases of a subset of follicular adenomatoid nodules with focal areas showing nuclear features characteristic of PTC, identified as WDT-UMP, were also analyzed. Immunohistochemical analysis of galectin-3, HBME-1, CK19 and the proliferation markers Ki67 and cyclin D1 was performed. Lesions were analyzed for cyclin D1 gene amplification by fluorescent in-situ hybridization. RESULTS: All WDT-UMP lesions showed immunolabelling of cyclin D1, Ki67; 11/ 13 cases showed immunolabelling of CK19; 10/13 cases showed immunolabelling of HBME-1 and 4/13 cases showed immunolabelling of galectin-3. Surrounding benign adenomatoid areas showed no to faint focal staining in all thirteen cases of cyclin D1, HBME-1 and galectin-3. A low rate of cyclin D1 gene amplification was identified in a significant proportion of cells in the WDT-UMP lesions as compared to surrounding benign adenomatoid areas. CONCLUSIONS: Increased expression of cyclin D1 and amplification of its gene along with immunolabelling of HBME-1 in WDT-UMP lesions showing cytological features of papillary thyroid carcinoma within follicular adenomatoid nodules suggest that these areas could correspond to a precursor lesion of follicular variant of PTC. Overexpression of cyclin D1, associated with the amplification of the gene suggests that these WDT-UMP lesions are an intermediate between the benign and malignant groups making this group of lesions a reliable precursor of FVPTC. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1851820807142117
format Online
Article
Text
id pubmed-4407836
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44078362015-04-24 Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential Lamba Saini, Monika Weynand, Birgit Rahier, Jacques Mourad, Michel Hamoir, Marc Marbaix, Etienne Diagn Pathol Research BACKGROUND: Encapsulated follicular tumours with equivocal papillary thyroid carcinoma (PTC) type nuclear features continue to remain a challenge despite the recent attempts to classify these borderline lesions. The term ‘well differentiated tumour of uncertain malignant potential (WDT-UMP)’ was introduced to classify these tumours. The present study aimed to evaluate the role of a cell cycle regulator like cyclin D1 in these tumours along with assessment of other well established PTC markers like galectin-3, HBME-1, CK19. METHODS: Thirteen cases of metastatic PTC, papillary microcarcinoma and follicular variant of PTC (FVPTC) were identified from a histological review of 510 cases. In addition, 13 cases of a subset of follicular adenomatoid nodules with focal areas showing nuclear features characteristic of PTC, identified as WDT-UMP, were also analyzed. Immunohistochemical analysis of galectin-3, HBME-1, CK19 and the proliferation markers Ki67 and cyclin D1 was performed. Lesions were analyzed for cyclin D1 gene amplification by fluorescent in-situ hybridization. RESULTS: All WDT-UMP lesions showed immunolabelling of cyclin D1, Ki67; 11/ 13 cases showed immunolabelling of CK19; 10/13 cases showed immunolabelling of HBME-1 and 4/13 cases showed immunolabelling of galectin-3. Surrounding benign adenomatoid areas showed no to faint focal staining in all thirteen cases of cyclin D1, HBME-1 and galectin-3. A low rate of cyclin D1 gene amplification was identified in a significant proportion of cells in the WDT-UMP lesions as compared to surrounding benign adenomatoid areas. CONCLUSIONS: Increased expression of cyclin D1 and amplification of its gene along with immunolabelling of HBME-1 in WDT-UMP lesions showing cytological features of papillary thyroid carcinoma within follicular adenomatoid nodules suggest that these areas could correspond to a precursor lesion of follicular variant of PTC. Overexpression of cyclin D1, associated with the amplification of the gene suggests that these WDT-UMP lesions are an intermediate between the benign and malignant groups making this group of lesions a reliable precursor of FVPTC. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1851820807142117 BioMed Central 2015-04-18 /pmc/articles/PMC4407836/ /pubmed/25907675 http://dx.doi.org/10.1186/s13000-015-0262-8 Text en © Lamba Saini et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lamba Saini, Monika
Weynand, Birgit
Rahier, Jacques
Mourad, Michel
Hamoir, Marc
Marbaix, Etienne
Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential
title Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential
title_full Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential
title_fullStr Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential
title_full_unstemmed Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential
title_short Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential
title_sort cyclin d1 in well differentiated thyroid tumour of uncertain malignant potential
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407836/
https://www.ncbi.nlm.nih.gov/pubmed/25907675
http://dx.doi.org/10.1186/s13000-015-0262-8
work_keys_str_mv AT lambasainimonika cyclind1inwelldifferentiatedthyroidtumourofuncertainmalignantpotential
AT weynandbirgit cyclind1inwelldifferentiatedthyroidtumourofuncertainmalignantpotential
AT rahierjacques cyclind1inwelldifferentiatedthyroidtumourofuncertainmalignantpotential
AT mouradmichel cyclind1inwelldifferentiatedthyroidtumourofuncertainmalignantpotential
AT hamoirmarc cyclind1inwelldifferentiatedthyroidtumourofuncertainmalignantpotential
AT marbaixetienne cyclind1inwelldifferentiatedthyroidtumourofuncertainmalignantpotential